Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Garcia, Donald
NCT04693351 / 2020-004653-69: Efficacy and Safety Study of Adjunctive Troriluzule in Obsessive Compulsive Disorder	Active, not recruiting	3	700	Europe, Canada, US, RoW	Troriluzole, Placebo	Biohaven Pharmaceuticals, Inc.	Obsessive-Compulsive Disorder	04/25	04/25
LIFT-AD, NCT04488419: ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease	Completed	2/3	554	US	ATH-1017, Placebo	Athira Pharma	Alzheimer Disease, Dementia of Alzheimer Type	07/24	07/24
NCT05729373: A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder	Recruiting	2/3	434	Europe, Japan, US	SEP-363856, Placebo	Otsuka Pharmaceutical Development & Commercialization, Inc.	Generalized Anxiety Disorder	02/26	02/26
NCT06419608: Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression	Recruiting	2	300	US	BHV-7000, Placebo	Biohaven Therapeutics Ltd.	Major Depressive Disorder	05/25	07/25

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Garcia, Donald
NCT04693351 / 2020-004653-69: Efficacy and Safety Study of Adjunctive Troriluzule in Obsessive Compulsive Disorder	Active, not recruiting	3	700	Europe, Canada, US, RoW	Troriluzole, Placebo	Biohaven Pharmaceuticals, Inc.	Obsessive-Compulsive Disorder	04/25	04/25
LIFT-AD, NCT04488419: ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease	Completed	2/3	554	US	ATH-1017, Placebo	Athira Pharma	Alzheimer Disease, Dementia of Alzheimer Type	07/24	07/24
NCT05729373: A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder	Recruiting	2/3	434	Europe, Japan, US	SEP-363856, Placebo	Otsuka Pharmaceutical Development & Commercialization, Inc.	Generalized Anxiety Disorder	02/26	02/26
NCT06419608: Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression	Recruiting	2	300	US	BHV-7000, Placebo	Biohaven Therapeutics Ltd.	Major Depressive Disorder	05/25	07/25